SIM
ALNY icon

Spark Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Spark Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-46,700
Closed -$3.39M – 395
2019
Q2 		$3.39M Buy
+46,700
New +$3.58M 0.23% 131
2018
Q2 		– Sell
-10,500
Closed -$1.25M – 653
2018
Q1 		$1.25M Buy
+10,500
New +$1.35M 0.08% 306

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Spark Investment Management's ALNY Position: Q3 2019 in Review

Spark Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2019, closing a stake of 46,700 shares — an estimated $3.39M sold.

Spark Investment Management first reported a position in ALNY in Q1 2018 and held it in 2 quarters. The position peaked at $3.39M in Q2 2019. 281 funds tracked by Wall St. Rank hold ALNY as of Q3 2019.

  • Spark Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Spark Investment Management sold 46,700 Alnylam Pharmaceuticals shares in Q3 2019, an estimated $3.39M.
  • Spark Investment Management first reported a position in Alnylam Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Spark Investment Management's Alnylam Pharmaceuticals position peaked at $3.39M in Q2 2019.
  • 281 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2019.

Based on Spark Investment Management's 13F filing for Q3 2019, filed 12 Nov 2019.